Incyte (INCY) Equity Average (2011 - 2026)
Incyte (INCY) reported Equity Average of $5.4 billion for Q1 2026, up 51.65% on a YoY basis from $3.6 billion in Q1 2025, and up 9.9% quarter-over-quarter from $4.9 billion in Q4 2025.
Incyte (INCY) Equity Average (2011 - 2026) Analysis & Trends
Incyte has reported Equity Average for 16 years, with the latest figure at $5.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 51.65% year-over-year to $5.4 billion; the trailing twelve-month figure through Mar 2026 stood at $5.4 billion (up 51.65% YoY), and the FY2025 full-year result was $4.3 billion, changed 0.26% from the prior year.
- Equity Average for Q1 2026 stood at $5.4 billion, up from $4.9 billion in the prior quarter.
- The five-year high for Equity Average was $5.4 billion in Q1 2026, with the low at $3.1 billion in Q3 2024.
- Historically, Equity Average has averaged $4.3 billion across 5 years, with a median of $4.3 billion in 2022.
- Annual changes were most pronounced in 2024 — Equity Average plunged 36.23% — and 2026, when it soared 51.65%.
- Incyte's Equity Average stood at $4.3 billion in 2022, then increased by 17.73% to $5.1 billion in 2023, then tumbled by 34.6% to $3.3 billion in 2024, then surged by 48.34% to $4.9 billion in 2025, then climbed by 9.9% to $5.4 billion in 2026.
- The last three Equity Average figures came in at $5.4 billion (Q1 2026), $4.9 billion (Q4 2025), and $4.4 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 5.40 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.40 Bn |
| Dec 31, 2025 | 4.91 Bn |
| Sep 30, 2025 | 4.41 Bn |
| Jun 30, 2025 | 3.92 Bn |
| Mar 31, 2025 | 3.56 Bn |
| Dec 31, 2024 | 3.31 Bn |
| Sep 30, 2024 | 3.08 Bn |
| Jun 30, 2024 | 4.20 Bn |
| Mar 31, 2024 | 5.29 Bn |
| Dec 31, 2023 | 5.06 Bn |
| Sep 30, 2023 | 4.84 Bn |
| Jun 30, 2023 | 4.60 Bn |
| Mar 31, 2023 | 4.42 Bn |
| Dec 31, 2022 | 4.30 Bn |
| Sep 30, 2022 | 4.16 Bn |
| Jun 30, 2022 | 3.97 Bn |
| Mar 31, 2022 | 3.82 Bn |
| Dec 31, 2021 | 3.46 Bn |
| Sep 30, 2021 | 3.04 Bn |
| Jun 30, 2021 | 2.83 Bn |